The baseline of hs-cTnT, NT-proBNP, Ann Arbor stage of NHL, ALL patients with a high tumor burden (blasts ≥20% in bone marrow), lymphodepletion regimens and underlying diseases (including diabetes, coronary artery disease, chronic heart failure and atrial fibrillation) were no statistical significance. The gene discussed is NPPB; the disease is atrial fibrillation.